Ellis Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
- Paid Up Capital ₹ 3.40 M
- Company Age 28 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.20 M
- Revenue Growth -2.15%
- Profit Growth -21.72%
- Ebitda -13.02%
- Net Worth 9.02%
- Total Assets -0.23%
About Ellis Pharma
Ellis Pharma Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 June 1996 and has a history of 28 years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.40 M.
The company has closed loans amounting to ₹6.20 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jamsa Soaib and Mazhar Mansuri serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ1996PTC029850
-
Company No.
029850
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Jun 1996
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Ellis Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jamsa Soaib
|
Director | 11-Sep-2018 | Current |
| Mazhar Mansuri | Director | 03-Aug-2024 | Current |
Financial Performance of Ellis Pharma.
Ellis Pharma Private Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 2.15% decrease. The company also saw a substantial fall in profitability, with a 21.72% decrease in profit. The company's net worth moved up by a moderate rise of 9.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ellis Pharma?
In 2019, Ellis Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹6.20 M
Charges Breakdown by Lending Institutions
- Small Industries Development Bank Of India : 0.50 Cr
- Union Bank Of India : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Apr 2004 | Small Industries Development Bank Of India | ₹5.00 M | Satisfied |
| 27 Dec 2002 | Union Bank Of India | ₹1.20 M | Satisfied |
How Many Employees Work at Ellis Pharma?
Ellis Pharma has a workforce of 7 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ellis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ellis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
